A comparison of budesonide with prednisolone for active Crohn's disease
1994
Background Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism in the liver, its systemic bioavailability is low. Methods We conducted a randomized, double-blind, 10-week trial comparing the efficacy and safety of an oral controlled-release form of budesonide with the efficacy and safety of prednisolone in 176 patients with active ileal or ileocecal Crohn's disease (88 patients in each treatment group). The dose of budesonide was 9 mg per day for eight weeks and then 6 mg per day for two weeks. The dose of prednisolone was 40 mg per day for two weeks, after which it was gradually reduced to 5 mg per day during the last week. Results At 10 weeks, 53 percent of the patients treated with budesonide were in remission (defined as a score ≤ 150 on the Crohn's disease activity index), as compared with 66 percent of those treated with prednisol...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
557
Citations
NaN
KQI